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According to the world health organization, 
there were approximately 36.9 million people 
worldwide living with HIV/AIDS at the end of 
2014. Sub Saharan Africa is the most affected 
region with 25.8 million people living with HIV 
in 2014 accounting for 70% of the global total of 
new HIV infection (Revill et al., 2015). As of 
2014 in Nigeria, the HIV prevalence rate among 
adults ages 15-49 was 3.17% making Nigeria the 
second-largest country with people living with 
HIV (CIA, 2014).  
The treatment of HIV is known as antiretroviral 
therapy which is a combination of several 
antiretroviral drugs used to slow the rates 
which HIV replicates (WHO 2010). A 
combination of 3 or more antiretroviral drugs is 
more effective than using just one drug 
(monotherapy) to treat HIV. This is because 
combination therapy reduces the development 
of drug resistance and also gives a synergistic 
effect in suppressing viral replication (Bozic et 
al., 2013). 
The classes of antiretroviral drugs includes the 
following; Nucleoside reverse transcriptase 
inhibitors (NRTIs) e.g. Abacavir, Didanosine, 
Lamivudine, Stavudine, Zidovudine, Tenofovir; 
Non- Nucleoside reverse transcriptase inhibitors 
(NNRTs) e.g. Efavirenz, Nevirapine, Rilpivirin, 
Etarivine; Protease inhibitors (PI) e.g. 
Atazanavir, Lopinavir, Ritonavir; Fusion 
inhibitors (FI) e.g. Enfuvirtide; Integrase 
Inhibitor (II) e.g. Raltegravir; CCR5 receptor 
antagonist e.g. Maraviroc The drugs are 
formulated in a fixed dose combination 
consisting of two NRTIs and one NNRTI. And in 
some cases, fixed dose combination of two 
drugs from the same class. 
The introduction of highly active antiretroviral 
therapy (HAART) in developed countries in the 
late 90s has been associated with a remarkable 
decrease in AIDS related mortality (CDC, 2005). 
These clinical benefits however are not without 
unwanted effects called ADRs. Just like every 
other drugs, ARVs have side effects and adverse 
drug reactions (ADRs).  
http://dx.doi.org/10.4314/bajopas.v11i1.52S 
ABSTRACT 
Antiretroviral therapy (ART) has reduced morbidity and mortality in HIV patients. In 
Nigeria, there are over 400,000 patients on ART in over 200 secondary and tertiary 
hospitals. However, data on adverse drug reactions (ADRs) due to ARTs are limited. The aim 
of this study was to evaluate ADRs reports in adult patients on ART in Ahmadu Bello 
University Teaching Hospital Zaria (ABUTH). The study was a retrospective cross-sectional 
study on randomly selected adult patients on ART with ADR reports in Nasara Clinic of 
ABUTH, between January, 2012 and December, 2013. Medical records and ADR reports of the 
patients were reviewed and fitted into a structured questionnaire. Data were analyzed 
using SPSS Version 20.0. The study reviewed the records of 302 patients on ART as per the 
sample size out of a total of 1405 patients in the register within the study period. Of the 
302 patients, 109 (36.1%) were reported to have at least one form of ADR, majority of 
whom were females 65 (59.6%). The most common ADRs were cough (34%), skin rash (44%), 
headache (20%) and diarrhea (10%), with few cases of anemia (5.5%), lipodostrophy (3.6%) 
and neuropathy (1.8%). 55% and 98% had concomitant disease and medications respectively. 
The actions taken to manage the ADR were; specific treatment of the ADR (69.7%), change of 
ARV regimen (22%) and few cases of hospitalization (6.4%). In conclusion, the study revealed 
the occurrence of ADRs in adult patients on ART in ABUTH. These reactions occurred within 
few months of medication, and were found to be related to age, social factor, ART regimen, 
gender, as well as other concomitant diseases and medications. Close monitoring is required 
to prevent severe ADR and improve adherence. 
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Adverse drug reaction is a broad term referred 
to unwanted, uncomfortable or dangerous 
effect that a drug may have (Tarloff, 2012).  
In the United States 3-7% of all hospitalized 
patients are due to adverse drug reactions 
(Tarloff, 2012). Incidence of ADRs vary by 
patients’ characteristics (e.g. Age, sex, 
ethnicity, co-existing disorders, genetic or 
geographic factors) and by drug factors 
(Tarloff, 2012). An adverse drug reaction is any 
noxious, undesired, or unintended response to a 
therapeutic agent/ which may be expected or 
unexpected, and may occur at dosages used for 
prophylaxis, diagnosis, or therapy of disease or 
for modifying physiologic function (WHO, 2010).  
Adverse drug reaction due to continuous 
exposure to antiretroviral drugs leaves the 
physician with few options; decreasing the 
dosage of ARVs thus compromising efficacy, 
withdrawing the offending drugs and 
substituting with another drug or 
symptomatically treating the ADR. However 
substituting the offending drug is difficult 
especially in resource limited settings, because 
most HAART regimens exists as fixed dose 
combinations (FDC) of different drugs most of 
which are first line drugs with high toxicity 
profiles (USAIDs, 2008). 
There are no known studies that provides 
reliable information on the ADRs in Northern 
Nigeria. This indicates the need for 
antiretroviral therapy safety surveillance in 
clinical settings. This study is therefore aimed 
at evaluating ADRs in adult patients on ART in 
Ahmadu Bello University Teaching Hospital 
Zaria (ABUTH). 
METHODS 
The study was a retrospective cross-sectional 
study on 302 randomly selected adult patients 
on ART in ABUTH between the periods of 
January, 2012 and December, 2013 out of a 
total of 1405 patients registered within this 
period. Following ethical approval form ABUTH 
ethical committee, medical records and ADR 
reports of the patients were reviewed and 
fitted into a structured questionnaire. Only 
adult HIV positive patients on ART within the 
period of the study were included. The data 
collected were presented in tables as 
descriptive and percentages. They were 
analyzed using the SPSS Version 20.0.  
 
RESULTS 
A. Baseline Characteristics of Study 
Population and Adverse Drug Reaction  
A total of 302 patients’ medical records were 
reviewed. 109 out of the 302 patients 
developed ADR giving a prevalence 36.0%. 
Majority of the patients were females (58.6%) 
and mostly aged below 45 years (77.9%).  
 
Table 1: Baseline Characteristics of Study Population with Adverse Drug Reaction 
Variable Category Number of ADR (%) 
Yes = 109 (36.1) No = 193 (63.9) 
Gender Male 
44 (40.4) 8 (42.0) 
Female 
65 (59.6) 112 (58.0) 
Age (Years) 18 – 25 
14 (12.8) 36 (18.7) 
26 – 35 
46 (42.2) 93 (48.2) 
36 – 45 
25 (22.9) 46 (23.8) 
46 – 55 
23 (21.1) 18 (9.3) 
56 Above 
1 (0.9) 0 (0.0) 
ADR = Adverse Drug Reaction 
 
A. Risk Factors Associated with Adverse Drug 
Reaction 
ADRs were more common in patients on 
TDF/3TC/EFV (38.5%). 38% of all pregnant 
women developed ADR. All patients smoking 
(100%) and those taking alcohol (83.3%) had 
ADRs. 56% of patients with co-morbidity and 
those on concomitant medication especially 
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Table 2: Risk Factors Associated with ADRs 
Variable Category Number of ADR (%) 
ART Regimen AZT/3TC/NVP 26 (23.9) 
 TDF/3TC/EFV 42 (38.5) 
 TDF/3TC 12 (11.0) 
 AZT/3TC 29 (26.6) 
Pregnancy Yes 8 (38) 
 No 13 (62) 
Comorbidity Yes 61 (56.0) 
No 48 (44.0) 
Concomitant Medication Septrin 75 (68.8) 
Dapsone 8 (7.3) 
Multivitamins 17 (15.6) 
Anti-Tuberculosis 7 (6.4) 
None 2 (1.8) 
Smoking Yes 6 (100) 
No 0 (0) 
Alcohol Consumption Yes 20 (83.3) 
No 4 (16.7) 
ART = Antiretroviral therapy; ADR =Adverse drug reaction; AZT = Zidovudine; 3TC = Lamivudine; 
NVP = Nevirapine; TDF = Tenofovir; EFV = Efaverenz; ADR = Adverse Drug Reaction 
 
B. Adverse Drug Reactions Encountered 
among the Study Population  
Patients totaling 109 (36.1%) on ART were 
found to have at least one form of ADR. The 
mild form of the ADRs was mostly encountered 
(68.8%). They include and not limited to Rashes 
(15.9%) and Cough (12.6%). Specific treatments 
were mostly given to the patients (69.8%). 
 
Table 3. ADRs encountered among the study population  
Variable Category n (%); N = 109 
Number of ADRs per patient  One 
42 (38.5) 
Two 20 (18.3) 
Three 17 (15.6) 
Four 22 (20.2) 
Above Four 8 (7.3) 
When ADR was experienced (Post 
medication) 
< 2 Weeks 4 (3.7) 
2 Weeks – 1 Month 66 (60.6) 
1 Month – 3 Months 37 (33.9) 
> 3 Months 2 (1.8) 
Severity of ADRs Mild 75 (68.8) 
Moderate 27 (24.8) 
Severe 7 (6.4) 
Interventions on ADR Change of drug regimen 24 (22.0) 
Specific treatment 76 (69.8) 
Hospitalization 7 (6.4) 
None 2 (1.8) 
 
DISCUSSION 
This study reviewed adverse drug reaction 
(ADR) in adult patients taking antiretroviral 
medications. ADRs were not uncommon among 
the studied population. The occurrence of ADRs 
were to a larger extent associated with the 
antiretroviral therapy (ART) regimens, gender, 
comorbidity, concomitant medications and age. 
ADR was higher in patients below 45 years 
(77.9%). This is similar to previous findings by 
Eluwa et al., (2012) who reported strong 
correlation of HIV with adolescence. Our study 
showed more females with ADRs (59.6%) 
compared to their males counterpart (40.3%). 
This is similar to the report by Bonfati et al., 
(2000) who observed that women experience 
significantly greater number of adverse effects. 
ADRs were found to occur within 1 month of 
initiating treatment (60.6%). 33.9% and 3.6% of 
the patients experienced ADRs in 1-3months 
and <2weeks of commencement of therapy 
respectively. 
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Similarly, Eluwa et al., (2012) reported that the 
likelihood of ADR occurrence is highest in the 
first 6 months. Close monitoring of patients 
within this time frame is thus imperative to 
prevent the occurrence of severe ADRs and 
improves adherence. Eluwa et al., (2012) also 
reported that 45% of reported ADRs occurred 
within 12-24months of commencing ART. 
However, this was not observed in this study 
due to poor long term documentation at the 
Centre. Some studies have proposed time-
dependent toxic accumulation as the 
mechanism of developing an ADR long after 
commencing medication.  
Most of the reported ADR were mild (66.9%), 
24.7% were moderate and 6.4% were severe. 
This suggests good tolerance level to ART in 
general. The commonest ADRs reported were 
cough, rash, itchy skin, headache, fever and 
diarrhea. Many of the cases of skin rash were 
reported in patients who received nevirapine-
based regimen. The major clinical toxicity of 
nevirapine is rash which has been reported in 
32% and 48% of patients (Tukukino et al., 
2008). National treatment guidelines 
recommend that a patient starting nevirapine 
should receive a 2-week lead-in dose (200mg 
once daily) to reduce the risk of rash and 
severity. 
Incidence of anemia was 5% which occurred 
exclusively in patients on AZT/3TC/NVP. This is 
similar to other studies carried out in Nigeria, 
Haiti and India that observed anemic rates of 3-
12% (Subbaraman et al., 2007 and Idoko et al., 
2002). 
Studies on the incidence of ADR from 
developing countries have reported incidence 
of ADR between 11-35.9% (Patrice et al., 2010; 
Bonfati et al., 2000). According to Dean et al., 
(2002), the incidence can occur as high as 54% 
in the presence of an opportunistic infection 
which is similar to this study where 55% of the 
patients had concomitant 
infection/disease/disorder. 
Specific treatments were instituted in patients 
with ADR. The fact that ADR could be life 
threatening, serious attention is encouraged in 
ameliorating the ADR. This will improve on the 
overall treatment outcome and adherence. 
 
CONCLUSION 
The study revealed the occurrence of Adverse 
Drug Reactions in adult patients on Anti-
retroviral Therapy in Ahmadu Bello University 
Teaching Hospital Zaria. These reactions 
occurred within few months of medication, and 
were found to be associated with regimen, 
gender, as well as other concomitant 
medications. Close monitoring is required to 
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